Aucta Company Profile
✉ Email this page to a colleague
What is the competitive landscape for AUCTA
AUCTA has eight approved drugs.
There are three US patents protecting AUCTA drugs.
There are nine patent family members on AUCTA drugs in twelve countries and eight supplementary protection certificates in five countries.
Summary for Aucta
| International Patents: | 9 |
| US Patents: | 3 |
| Tradenames: | 8 |
| Ingredients: | 8 |
| NDAs: | 8 |
Drugs and US Patents for Aucta
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Aucta | MOTPOLY XR | lacosamide | CAPSULE, EXTENDED RELEASE;ORAL | 216185-003 | May 4, 2023 | RX | Yes | Yes | 11,883,374 | ⤷ Start Trial | Y | ⤷ Start Trial | |||
| Aucta | VIGADRONE | vigabatrin | FOR SOLUTION;ORAL | 210196-001 | Jun 21, 2018 | AA | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ||||
| Aucta | MOTPOLY XR | lacosamide | CAPSULE, EXTENDED RELEASE;ORAL | 216185-002 | May 4, 2023 | RX | Yes | No | 12,042,474 | ⤷ Start Trial | Y | ⤷ Start Trial | |||
| Aucta | MOTPOLY XR | lacosamide | CAPSULE, EXTENDED RELEASE;ORAL | 216185-002 | May 4, 2023 | RX | Yes | No | 11,337,943 | ⤷ Start Trial | Y | ⤷ Start Trial | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for Aucta Drugs
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| Lithuania | 3981390 | ⤷ Start Trial |
| World Intellectual Property Organization (WIPO) | 2020244615 | ⤷ Start Trial |
| China | 114404393 | ⤷ Start Trial |
| European Patent Office | 3981390 | ⤷ Start Trial |
| >Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for Aucta Drugs
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 0914118 | SPC/GB07/002 | United Kingdom | ⤷ Start Trial | SUPPLEMENTARY PROTECTION CERTIFICATE NO SPC/GB07/002 GRANTED TO NOVARTIS AG IN RESPECT OF THE PRODUCT DEFERASIROX AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF, ESPECIALLY 4-(3,5-BIS(2-HYDROXYPHENYL)-(1,2,4) TRIAZOL-L-YL) BENZOIC ACID, THE GRANT OF WHICH WAS ADVERTISED IN JOURNAL NO 6179 DATED 24 OCTOBER 2007 HAS HAD ITS MAXIMUM PERIOD OF DURATION CORRECTED, SUBJECT TO THE PAYMENT OF THE PRESCRIBED FEES IT WILL EXPIRE ON 30 AUGUST 2021. |
| 0888289 | SPC/GB09/007 | United Kingdom | ⤷ Start Trial | PRODUCT NAME: LACOSAMIDE AND ITS PHARMACEUTICALLY ACCEPTABLE FORMS; REGISTERED: UK EU/1/08/470/001 20080829; UK EU/1/08/470/002 20080829; UK EU/1/08/470/003 20080829; UK EU/1/08/470/004 20080829; UK EU/1/08/470/005 20080829; UK EU/1/08/470/006 20080829; UK EU/1/08/470/014 20080829; UK EU/1/08/470/015 20080829; UK EU/1/08/470/016 20080829; UK EU/1/08/470/007 20080829; UK EU/1/08/470/008 20080829; UK EU/1/08/470/009 20080829; UK EU/1/08/470/010 20080829; UK EU/1/08/470/012 20080829; UK EU/1/08/470/013 20080829 |
| 0888289 | C300376 | Netherlands | ⤷ Start Trial | PRODUCT NAME: LACOSAMIDE; REGISTRATION NO/DATE: EU/1/08/470/001-016 20080829 |
| 0914118 | PA2007001,C0914118 | Lithuania | ⤷ Start Trial | PRODUCT NAME: DEFERASIROXUM; REGISTRATION NO/DATE: EU/1/06/356/001 2006-08-28, EU/1/06/356/002 2006-08-28, EU/1/06/356/003 2006-08-28, EU/1/06/356/004 2006-08-28, EU/1/06/356/005 2006-08-28, EU/1/06/356/00 20060828 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
